Physician profile
Jayant Viradia
NPI 1881616084
$806.82
in general payments reported to CMS, 2019-2025
15 companies · $185 in 2025
The $185 reported for 2025 was more than what 79% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.04 · 2020: $180 · 2021: $107 · 2022: $40.56 · 2023: $56.40 · 2024: $217 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $218.79 | 2024-2025 | Tremfya, Stelara, Simponi |
| Merck Sharp & Dohme LLC | $112.61 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.14 | 2020-2024 | Xifaxan |
| Redhill Biopharma INC. | $63.78 | 2020-2021 | |
| Genzyme Corporation | $61.19 | 2023-2025 | |
| Abbott Laboratories | $57.75 | 2024 | Xience Skypoint |
| Takeda Pharmaceuticals U.S.A., INC. | $48.12 | 2019-2024 | Entyvio |
| Bioprotect Medical, INC. | $29.85 | 2025 | Bioprotect Balloon Implant System |
| Daiichi Sankyo INC. | $28.62 | 2021-2022 | |
| Axonics, INC. | $24.90 | 2021 | |
| Ardelyx, INC. | $16.79 | 2024 | Ibsrela |
| Urogen Pharma, INC. | $16.47 | 2023 | Jelmyto |
| Nestle Healthcare Nutrition INC. | $14.51 | 2022 | |
| Myriad Genetic Laboratories, INC. | $13.76 | 2022 | |
| Aimmune Therapeutics, INC. | $13.54 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayant Viradia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.